Treatment of Pituitary Gigantism in X-Linked Acrogigantism Due to Chromosome Xq26.3 Duplication (GPR101)
X-linked acrogigantism (X-LAG) is the earliest-onset form of pituitary gigantism. It is caused by duplications on chromosome Xq26.3 involving the GPR101 gene, leading to unchecked GH and IGF-1 excess beginning in infancy.
Clinical scenario
Children with X-LAG typically develop signs of accelerated overgrowth — markedly increased height and weight — within the first 12–36 months of life. This presentation, driven by the GPR101 Xq26.3 duplication, distinguishes X-LAG from later-onset forms of pituitary gigantism and shapes the treatment approach.
Treatment goals
The primary objective is control of excess GH and IGF-1 secretion.
Approach (partial overview)
Initial management may involve a surgical approach or a first-generation somatostatin analog, depending on individual circumstances.
References
DOI: 10.1016/B978-0-12-814537-1.00002-6
- Duplications on chromosome Xq26.3 involving the gene GPR101 are responsible for X-LAG, the earliest onset form of pituitary gigantism described.
- Patients with X-LAG typically develop signs of overgrowth in the first 12–36 months of life, with increased height and weight becoming increasingly prominent over time.
- Initial management of X-LAG usually involves the use of surgery or first-generation somatostatin analogs.
- To control X-LAG surgically, a complete resection of the tumor and/or hyperplasia is required, as very small tumor remnants can maintain excess GH and IGF-1 secretion, in some cases for decades.